Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

December 31, 2028

Study Completion Date

March 31, 2029

Conditions
Von Willebrand Disease
Interventions
BIOLOGICAL

Alphanate SD/HT

A general guideline based on the product Full Prescribing Information is recommended with a maximum dose of 80 VWF:RCof IU/kg. The number of administrations before, during, and after the surgery procedure depends on the subject's clinical condition and the type of surgery itself. Single administrations or multiple doses may be appropriate. The dose of Alphanate® administered to each subject will be recorded as IU of VWF:RCof and also as IU of FVIII:C. The lot number for each vial of concentrate administered will also be recorded.

All Listed Sponsors
lead

Grifols Biologicals, LLC

INDUSTRY